China sets higher bar for consumer finance companies
CHINA has changed the rules for consumer finance firms for the first time in a decade, setting a higher bar for non-bank financial businesses providing small personal loans in the world’s second-largest economy.
The stricter measures, which will take effect on Apr 18, come amid a regulatory tightening across China’s financial sector, despite the economy’s wobbly post-Covid recovery, and analysts see them as potentially deterring new players.
The revised rules, published by the National Financial Regulatory Administration (NFRA) after a one-month consultation ended mid-January, are in line with the proposed amendments.
Under the new regulation, firms that provide consumer financing for other than home and car purchases must have a minimum registered capital of one billion yuan (S$186 million), more than three times the minimum 300 million yuan required under 2014 regulation.
A major investor in a consumer finance firm must also hold a stake of at least 50 per cent, up from 30 per cent previously.
Financial institutions that are major investors must have total assets of at least 500 billion yuan by the end of the most recent fiscal year, up from 60 billion yuan previously.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
A non-financial major investor, meanwhile, needs to have at least 60 billion yuan in operating income in the most recent fiscal year, double the previously required number. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Singapore developer in limbo after Timor-Leste scraps major township project
That ‘cheap’ Malaysia condo could cost Singapore buyers far more than they think
Gojek founder Nadiem Makarim faces 18-year jail demand in Indonesia laptop graft trial